These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24371062)

  • 1. Developing high-throughput HIV incidence assay with pyrosequencing platform.
    Park SY; Goeken N; Lee HJ; Bolan R; Dubé MP; Lee HY
    J Virol; 2014 Mar; 88(5):2977-90. PubMed ID: 24371062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precision detection of recent HIV infections using high-throughput genomic incidence assay.
    Faraci G; Park SY; Love TMT; Dubé MP; Lee HY
    Microbiol Spectr; 2023 Sep; 11(5):e0228523. PubMed ID: 37712639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing a genome-based HIV incidence assay with high sensitivity and specificity.
    Park SY; Love TM; Nelson J; Thurston SW; Perelson AS; Lee HY
    AIDS; 2011 Oct; 25(16):F13-9. PubMed ID: 21716075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
    Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
    J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIITE: HIV-1 incidence and infection time estimator.
    Park SY; Love TMT; Kapoor S; Lee HY
    Bioinformatics; 2018 Jun; 34(12):2046-2052. PubMed ID: 29438560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased specificity of an assay for recent infection in HIV-1-infected patients on highly active antiretroviral treatment: implications for incidence estimates.
    Chaillon A; Le Vu S; Brunet S; Gras G; Bastides F; Bernard L; Meyer L; Barin F
    Clin Vaccine Immunol; 2012 Aug; 19(8):1248-53. PubMed ID: 22718132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep Sequencing of the HIV-1 env Gene Reveals Discrete X4 Lineages and Linkage Disequilibrium between X4 and R5 Viruses in the V1/V2 and V3 Variable Regions.
    Zhou S; Bednar MM; Sturdevant CB; Hauser BM; Swanstrom R
    J Virol; 2016 Aug; 90(16):7142-58. PubMed ID: 27226378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Evaluation of a Modified Fourth-Generation Human Immunodeficiency Virus Enzyme Immunoassay for Cross-Sectional Incidence Estimation in Clade B Populations.
    Kirkpatrick AR; Patel EU; Celum CL; Moore RD; Blankson JN; Mehta SH; Kirk GD; Margolick JB; Quinn TC; Eshleman SH; Laeyendecker O
    AIDS Res Hum Retroviruses; 2016 Aug; 32(8):756-62. PubMed ID: 26988426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of two measures of HIV diversity in multi-assay algorithms for HIV incidence estimation.
    Cousins MM; Konikoff J; Sabin D; Khaki L; Longosz AF; Laeyendecker O; Celum C; Buchbinder SP; Seage GR; Kirk GD; Moore RD; Mehta SH; Margolick JB; Brown J; Mayer KH; Kobin BA; Wheeler D; Justman JE; Hodder SL; Quinn TC; Brookmeyer R; Eshleman SH
    PLoS One; 2014; 9(6):e101043. PubMed ID: 24968135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys.
    Andersson E; Shao W; Bontell I; Cham F; Cuong do D; Wondwossen A; Morris L; Hunt G; Sönnerborg A; Bertagnolio S; Maldarelli F; Jordan MR
    Infect Genet Evol; 2013 Aug; 18():125-31. PubMed ID: 23583545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High avidity anti-integrase antibodies discriminate recent and non-recent HIV infection: Implications for HIV incidence assay.
    Rikhtegaran Tehrani Z; Azadmanesh K; Mostafavi E; Gharibzadeh S; Soori S; Azizi M; Khabiri A
    J Virol Methods; 2018 Mar; 253():5-10. PubMed ID: 29248529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 drug resistance mutations detection and HIV-1 subtype G report by using next-generation sequencing platform.
    Gholami M; Rouzbahani N; Samiee S; Tayeri K; Ghorban K; Dehkharghani AD; Gholami AA; Moshiri F; Sattari A; Dadmanesh M; Mohraz M
    Microb Pathog; 2020 Sep; 146():104221. PubMed ID: 32360523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States.
    Konikoff J; Brookmeyer R; Longosz AF; Cousins MM; Celum C; Buchbinder SP; Seage GR; Kirk GD; Moore RD; Mehta SH; Margolick JB; Brown J; Mayer KH; Koblin BA; Justman JE; Hodder SL; Quinn TC; Eshleman SH; Laeyendecker O
    PLoS One; 2013; 8(12):e82772. PubMed ID: 24386116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequence ambiguity determined from routine pol sequencing is a reliable tool for real-time surveillance of HIV incidence trends.
    Lunar MM; Židovec Lepej S; Poljak M
    Infect Genet Evol; 2019 Apr; 69():146-152. PubMed ID: 30682549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal trends of recent HIV-1 infections in Slovenia (1986-2012) determined using an incidence algorithm.
    Lunar MM; Matković I; Tomažič J; Vovko TD; Pečavar B; Poljak M
    J Med Virol; 2015 Sep; 87(9):1510-6. PubMed ID: 25970253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HIV Genomic Incidence Assay Meets False Recency Rate and Mean Duration of Recency Infection Performance Standards.
    Park SY; Love TMT; Reynell L; Yu C; Kang TM; Anastos K; DeHovitz J; Liu C; Kober KM; Cohen M; Mack WJ; Lee HY
    Sci Rep; 2017 Aug; 7(1):7480. PubMed ID: 28785052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.
    Silver N; Paynter M; McAllister G; Atchley M; Sayir C; Short J; Winner D; Alouani DJ; Sharkey FH; Bergefall K; Templeton K; Carrington D; Quiñones-Mateu ME
    AIDS Res Ther; 2018 Nov; 15(1):18. PubMed ID: 30409215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality score based identification and correction of pyrosequencing errors.
    Iyer S; Bouzek H; Deng W; Larsen B; Casey E; Mullins JI
    PLoS One; 2013; 8(9):e73015. PubMed ID: 24039850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Automatic Analysis of Ultradeep Pyrosequencing Raw Data to Determine Percentages of HIV Resistance Mutations in Patients Followed-Up in Hospital.
    Bellecave P; Recordon-Pinson P; Fleury H
    AIDS Res Hum Retroviruses; 2016 Jan; 32(1):85-92. PubMed ID: 26529549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing.
    Simen BB; Braverman MS; Abbate I; Aerssens J; Bidet Y; Bouchez O; Gabriel C; Izopet J; Kessler HH; Stelzl E; Di Giallonardo F; Schlapbach R; Radonic A; Paredes R; Recordon-Pinson P; Sakwa J; St John EP; Schmitz-Agheguian GG; Metzner KJ; Däumer MP;
    J Virol Methods; 2014 Aug; 204():31-7. PubMed ID: 24731928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.